Confidence comes with blood culture results you can trust.
With one squeeze, the Steripath® Gen2 Initial Specimen Diversion Device® diverts and sequesters the most commonly contaminated portion of the blood prior to collection – ensuring specimen integrity —giving nurses, CNOs, and laboratorians the confidence that they are providing the very best patient care possible.
Get Started Today
Speak with a Clinical Specialist to get started down your path to Culture Confidence.
of significantly reducing blood culture contamination can make a huge impact at your hospital
What makes Steripath so effective?
Steripath's proprietary technology and easy-to-use design enable you to deliver the definitive diagnostic results your patients deserve
Evidence-Based Diversion Volume
1.5-2.0mL is the diversion volume clinically proven effective in peer-reviewed, published, controlled studies.8
User-Controlled Active Diversion
Gentle negative pressure assists in drawing the diverted blood, critical for hard stick patients.
Uniquely designed to prevent the end-user from collecting the specimen until diversion is complete.
Clinically Proven for IV Starts
Steripath has been clinically proven effective with peripheral IV starts and venipuncture.*
Secondary Collection Pathway
A secondary blood collection pathway automatically opens for specimen collection once diversion is complete.
Available in a Customizable Kit
Everything you need to standardize blood culture collection best practices.
"Steripath may be the easiest and fastest route to significantly impact antibiotic stewardship within the hospital."
Lindsey Nielsen, PhD, CPEP Fellow, University of Nebraska Medical Center
- Indicated to reduce the frequency of blood culture contamination when contaminants are present, compared to standard method controls without diversion
- Additional terms and conditions may apply
- Robert Garcia, et al., "Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremia, reducing contamination, and eliminating false-positive central line associated bloodstream infections." American Journal of Infection Control, 2017
- D. Chang, et al. “Impact of Blood Culture Diversion Device and Molecular Pathogen Identification on Vancomycin Use.” Society of Healthcare Epidemiology of America (SHEA) Conference (Spring 2017)
- Skoglund, E., et al (2019). “Estimated Clinical and Economic Impact Through Use of a Novel Blood Collection Device [Steripath] to Reduce Blood Culture Contamination in the Emergency Department: A Cost-Benefit Analysis.” J Clin Microbiol. 57: e01015-18
- Boyce et al., "Obtaining Blood Cultures by Venipuncture versus from Central Lines: Impact on Blood Culture Contamination Rates and Potential Effect on Central Line–Associated Bloodstream Infection Reporting." AJIC 2013
- Reveles, et al, "The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010." AJIC 2014
- Richard G. Patton Blood Culture Contamination Definitions Can Obscure the Extent of Blood Culture Contamination: A New Standard for Satisfactory Institution Performance Is Needed. Infection Control & Hospital Epidemiology, Available on CJO 2016 doi:10.1017/ice.2016.30
* Multiple studies (Rupp M., et al; “Reduction in Blood Culture Contamination Through Use of Initial Specimen Diversion Device.” Clinical Infectious Diseases (Aug. 2017); Bell, M., et al. (2018). Effectiveness of a Novel Specimen Collection System in Reducing Blood Culture Contamination Rates. Journal of Emergency Nursing, 44(6): 570-5753; Zimmerman, F., et al.: “Reducing blood culture contamination using an initial specimen diversion device. American Journal of Infection Control (2018); Chang D., et al; Impact of Blood Culture Diversion Device and Molecular Pathogen Identification on Vancomycin Use. Society of Healthcare Epidemiology of America (SHEA) Conference (Spring 2017); Doern, G., et al. “A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem.” Clinical Microbiology Reviews (2019); Skoglund, E., et al.: "Estimated Clinical and Economic Impact Through Use of a Novel Blood Collection Device (Steripath) to Reduce Blood Culture Contamination in the Emergency Department: A Cost-Benefit Analysis.” J Clin Microbiol. (2019); Geisler, B., et al.: “A Model to Evaluate the Impact of Hospital-Based Interventions Targeting False-Positive Blood Cultures on Economic and Clinical Outcomes.” Journal of Hospital Infection (2019))